Fig. 2: MVA–MARV–VLP vaccine elicits binding and neutralizing antibodies. | npj Vaccines

Fig. 2: MVA–MARV–VLP vaccine elicits binding and neutralizing antibodies.

From: Modified vaccinia Ankara vaccine expressing Marburg virus-like particles protects guinea pigs from lethal Marburg virus infection

Fig. 2: MVA–MARV–VLP vaccine elicits binding and neutralizing antibodies.

Guinea pigs at five animals per group were vaccinated or mock-vaccinated at days 0 and 29. Sera collected 27 days post inoculation were assessed for their ability to bind to MARV Angola GP (a, b) and to neutralize MARV strain Angola (c, d). The MVA–MARV–VLP group is shown in red, the control group in black. P values were determined by 2-way ANOVA followed by Bonferroni post-test. Sera collected after the first (e) and the second (f) vaccine dose were analyzed for binding to peptides matching the protein sequence of MARV Angola GP. Values are Log10 mean ± SEM representing the binding of sera from three responders as a percentage of the binding of pre-immune sera. A linear map of MARV GP domains is displayed as a diagram below each graph: signal peptide (yellow, 1–18 aa); receptor-binding domain (orange, 38–188 aa); mucin-like domain (red, 257–501 aa); wing region (dark blue, 436–501 aa); internal fusion loop (dark gray, 511–552 aa); N-terminal heptad repeat (light green, 553–596 aa); CX6CC motif (purple, 602–610 aa); C-terminal heptad repeat (salmon, 616–633 aa); membrane-proximal external region (cyan, 634–655 aa); transmembrane anchor (dark green, 659–667 aa); and cytoplasmic tail (light gray, 674–681 aa). The furin cleavage site is marked by the triangle.

Back to article page